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Human immunodeﬁciency virus (HIV) vaccines have the potential to improve antiretroviral drug treatment by
inducing cytotoxic killing of HIV-infected cells. Prophylactic vaccines utilize new antigens to initiate immunity;
however, in HIV-infected individuals the load of viral antigen is not the limiting factor for the restoration of immune
responses. Here we describe a novel immunization strategy with DermaVir that improves viral antigen presentation
using dendritic cells (DC). DermaVir contains a distinctive plasmid DNA expressing all HIV proteins except integ-
rase to induce immune responses with broad speciﬁcity. The DNA is formulated to a mannosilated particle to target
antigen-presenting cells and to protect the DNA from intracellular degradation. After topical application, DermaVir-
transduced cells migrate from the skin to the draining lymph node and interdigitate as DermaVir-expressing,
antigen-presenting DC. We compared the immunogenicity of topical and ex vivo DC-based DermaVir vaccinations
in naı¨ve rhesus macaques. Both vaccinations induced simian immunodeﬁciency virus-specific CD4 helper and CD8
memory T cells detected by an in vivo skin test and an in vitro intracellular cytokine-based assay. Topical DermaVir
vaccination represents an improvement upon existing ex vivo DC-based immunization technologies and may pro-
vide a new therapeutic option for HIV-infected patients.
Key words: cellular immunity/dendritic cells/skin/therapy/topical vaccine
J Invest Dermatol 124:160 –169, 2005
One strategy for a new immunotherapeutic intervention
against human immunodeficiency virus (HIV) infection is to
develop a vaccine that can reconstitute HIV-specific immu-
nity, thereby improving the efficacy of the present antiretro-
viral regimens. The therapeutic efficacy of such a vaccine
would be mediated by HIV-specific T cells, which play a
central role in the control of virus replication (Amara and
Robinson, 2002; Lisziewicz et al, 2003). Therapeutic vac-
cines are conceptually different from preventive vaccines.
Preventive vaccines must prime the immune system with
foreign viral antigens to induce immune responses that
protect individuals from infection. In contrast, HIV-infected
individuals have already developed immune responses to
HIV, although insufficient to fully suppress virus replication
in the majority of patients. In these subjects, HIV is ex-
pressed in most organs and viral load exceeds several
thousands of viral RNA copies per milliliter in the peripheral
blood. Consequently, the load of viral antigen is not the
limiting factor in the induction of potent immune responses.
Since it is unlikely that additional viral antigen would provide
therapeutic benefit, we focused on the improvement of an-
tigen presentation in order to induce functional HIV-specific
T cells that could destroy HIV-infected cells.
We developed a new DNA-containing vaccine, called
DermaVir, that presents viral antigens by dendritic cells
(DC), the most potent type of antigen-presenting cell (APC)
(Banchereau and Steinman, 1998), to improve antigen pres-
entation during therapeutic immunization of chronically HIV-
infected individuals. We have previously described an
ex vivo vaccination strategy that uses DermaVir-transduced
autologous monocyte-derived DC for the induction of HIV-
specific T cells (Lisziewicz et al, 2001), and others have re-
cently shown control of simian immunodeficiency virus (SIV)
by ex vivo DC-based vaccination (Lu et al, 2003). DC-based
vaccines using ex vivo cell manipulation are, however, in-
herently limited by their cumbersome nature. To improve
upon this technology, we explored APC in the skin and their
ability to deliver the vaccine in vivo to the secondary lymph-
oid organs.
The skin is a physical barrier between the internal milieu
and the external world, the latter including its pathogens.
The epidermis contains a large number of Langerhans cells
(LC) (400–1,000 per mm2), which take up and process
epicutaneous antigens and migrate to the draining lymph
nodes. Although in transit, they begin to differentiate into
DC that present the processed antigens to naı¨ve T cells
(Steinman et al, 1995, 1997). The transfer of antigens to the
lymphoid organs is critical for the induction of immune re-
sponses (Zinkernagel et al, 1997). Immune responses are
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initiated in these lymphoid tissues, where antigen-loaded
DC encounter and activate T cells (Steinman, 1991; La-
nzavecchia and Sallusto, 2000). T cell activation results in
the generation of both effector and memory cells that play
distinctive roles against viral infection (von Andrian and
Mackay, 2000; Masopust et al, 2001; Reinhardt et al, 2001).
Therefore, LC in the epidermis might be used as a vehicle to
transfer antigens from the skin to the lymphoid organs.
For the treatment of HIV/AIDS, we have improved the
ex vivo DC vaccination technology with topical administra-
tion. DermaVir is administered to the surface of the skin with
the aim of targeting epidermal LC and transferring DNA into
these APC for presentation of viral antigens to T cells in
order to induce new, functional HIV-specific T cells. The ra-
tionale of this design is based on the following observations:
(i) early treatment of primary HIV/SIV infection, where DC
are the major APC (Rowland-Jones, 1999), induced T cell-
mediated immune responses that controlled virus replica-
tion after treatment interruption in SIV-infected macaques
(Lifson et al, 2000; Lori et al, 2000) and in some HIV-infected
individuals (Lisziewicz et al, 1999; Rosenberg et al, 2000); (ii)
in contrast, chronic infection, where DC are not the major
APC, is characterized by functionally impaired HIV-specific
T cells (Lieberman et al, 2001) that could account for the
lack of T cell-mediated viral clearance and rebound of virus
replication during treatment interruption (Bonhoeffer et al,
2000; Miller et al, 2000; Deeks et al, 2001; Garcia et al, 2001;
Lori and Lisziewicz, 2001; Ruiz et al, 2001); (iii) during es-
tablished infection, cell-mediated immune responses sup-
press SIV/HIV (Bagnarelli et al, 1994; Cao et al, 1995; Klein
et al, 1995; Harrer et al, 1996; Rosenberg et al, 1997; Ogg
et al, 1998; Lori et al, 1999; Pitcher et al, 1999; Pontesilli
et al, 1999; Schmitz et al, 1999), whereas humoral immune
responses do not appear to play a major role in viral control
(Wei et al, 2003).
The design of DermaVir as a therapeutic vaccine is dis-
tinct from most DNA vaccines developed for the prevention
of SIV/HIV infection in the following ways: (i) the DNA con-
struct mimics viral gene expression; (ii) epitopes derived
from the DNA antigen are presented by DC in the lymph
nodes; (iii) the vaccine is applied topically; and (iv) the vac-
cine induces Th-1 polarized HIV-specific T cells.
Results
Novel plasmid DNA in DermaVir for broad antigen pres-
entation Since our goal was to develop a vaccine for the
treatment of HIV, we wanted to use a DNA construct that
mimics the expression of the wild-type virus in DC as it
occurs during primary infection (Rowland-Jones, 1999).
HIV-LTR-driven viral protein expression is efficient and does
not require codon optimization. More importantly, it results
in processing of most viral proteins and presentation of T
cell epitopes, which is a key feature of the DermaVir vac-
cine. It has been recently demonstrated that DNA vaccina-
tion induced only a few epitopes that were identical to
epitopes induced by the wild-type virus (Vogel et al, 2002).
We have previously demonstrated that integrase-defective
HIV-1 can express in DC but is not able to establish a pro-
ductive infection, replicate, and integrate (Lisziewicz et al,
2001). To further characterize DermaVir in a relevant primate
model we constructed a similar integrase mutant plasmid,
pSHIV(int-), encoding a mutant pathogenic simian human
immunodeficiency virus (SHIV 89.6P) (Reimann et al, 1996;
Karlsson et al, 1997). This plasmid DNA can express
both regulatory (e.g. tat, rev, nef) and structural proteins
(e.g. gag, env), and is therefore expected to induce T cell-
mediated immune responses with broad specificity (Fig 1).
Application of DermaVir DermaVir is applied topically to
the surface of the skin after an exfoliation procedure. Shav-
ing and exfoliation removes part of the stratum corneum,
which rapidly regenerates. LC are located in the epidermis
under the stratum corneum as a network of immune sen-
tinels approximately 1000 cells per mm2 to protect the body
against pathogens that might enter upon injury to the skin.
Disruption of the stratum corneum is required for the pen-
etration of DermaVir to the epidermis and targeting of LC.
The migration of LC is induced either by DermaVir applica-
tion, which mimics a pathogen, or by the cytokines secreted
by nearby keratinocytes upon exfoliation of the skin, or
both. These ‘‘danger’’ signals are thought to trigger the LC
to leave the epidermis and migrate via the lymphatic vessels
to the draining lymphoid organs (Dieu-Nosjean et al, 1999).
Histological and macroscopic evaluation of DermaVir
vaccination in non-human primates demonstrated that the
skin exfoliation we developed for topical DermaVir admin-
istration is associated with the removal of the stratum corn-
eum and preservation of the epidermis (Fig 2a–d). In such
circumstances, it is unlikely that DermaVir would diffuse to
the dermis and target dermal DC; however, we do not rule
out this possibility. From the safety point of view, the pri-
mate study showed mild and transient erythema associated
with skin preparation (Fig 2e–g), and lack of systemic toxic-
ity. The safety results in primates were supported by a study
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Figure 1
The plasmid DNA of DermaVir. Map of the plasmid
DNA, pSHIV(int-), used for DermaVir vaccination in rhe-
sus macaques. A mutation in the integrase gene has
molecularly inactivated the full-length proviral DNA.
Such a plasmid DNA is capable of effective gene ex-
pression upon transfection of 293T cells (data not
shown). Virus replication is completely impaired in the
absence of integration. LTR, gag, pol, and nef sequenc-
es originate from SIVmac239 (no fill). Env, tat, and rev
genes originate from HIV-1. Env and second exons of
tat and rev (light gray) are from the 89.6p isolate of HIV-
1; others (dark gray) are from HXBc2.
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performed in swine, an accepted animal model for treat-
ments administered via the skin, as porcine skin is similar in
structure to human skin. Local reaction was limited to mild
transient erythema that did not occur every time. There was
no systemic toxicity, measured by blood chemistry and he-
matology, associated with DermaVir (data not shown).
Mechanism of DermaVir vaccination To activate naı¨ve T
cells, LC must undergo maturation when exposed to anti-
gens and migrate to the draining lymph node. Therefore, we
examined DermaVir-derived gene expression using RT-PCR
in the draining lymph nodes after topical DermaVir vacci-
nation in two different murine models; BALB/C and
C57BL/6 (Table I). DermaVir was formulated with Gag-
delta8.2, designated as pGag instead of the pSHIV(int-),
because the LTR promoter does not result in gene expres-
sion in mice. pGag was a suitable reporter gene because
gag mRNA can be quantified by a quantitative RT-PCR as-
say (Bagnarelli et al, 1994). Control animals were similarly
treated with DermaVir formulated with pGFP. We found over
30,000 copies of gag mRNA per 106 cells in the inguinal
lymph node of both mice species after vaccination with
DermaVir. In contrast, we found less than 4,000 copies of gag
mRNA per 106 cells in the lymph nodes of mice vaccinated
with the same formulation containing a control DNA. This
value was similar to that found in several untreated control
mice (average of 4,536; SD¼ 1,610). We suspect that the
gag-specific RT-PCR reaction gives a background in the dif-
ferent murine models, probably because of interference from
endogenous retroviruses that are common in mice.
Figure 2
Topical application of DermaVir.
DermaVir is applied to the surface of the
skin after a skin preparation procedure
causing the disruption of the stratum
corneum by exfoliation that allows the
vaccine to access the epidermis. Exfolia-
tion is performed by rubbing the skin 50
times with an exfoliation sponge (3M,
Heavy Duty). There is no hemorrhage,
and in most cases mild and transient ery-
thema is observed that is associated with
skin preparation, not administration of
DermaVir. (a–d) H&E-stained skin biop-
sies of two rhesus macaques, #942 and
947, prior to (a, c) and after (b, d) skin
preparation. The typical local reaction af-
ter topical DermaVir administration dem-
onstrated on clinical pictures of a rhesus
macaque (e–g). The inguinal region before
exfoliation (e), immediately following ex-
foliation and DermaVir application (f) (two
treatment areas shown in the box), and
15 min post-DermaVir application (g).
SC, stratum corneum; E, epidermis; D,
dermis.
Table I. Detection of HIV-1 Gag mRNA by RT-PCR in the lymph
nodes of mice after DermaVir vaccination
Animal DNA in DermaVir (gag)copies per 106 cells
BALB/C pGag 32,800
BALB/C pGFP o5000
C57BL/6 pGag 64,104
C57BL/6 pGFP o5000
Average control RT-PCR in different species of untreated mice was
4536 (SD¼ 1610). Values represented as o5000 copies are not different
from the negative control mice.
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To visualize the RNA-expressing cells in the lymph nodes
of DermaVir-vaccinated mice, in situ hybridization experi-
ments were carried out, using another reporter DNA con-
struct encoding the neomycin-phosphotransferase gene
(Neo). Figure 3a–d demonstrate the DNA-expressing cells
migrating into the lymph node 24 h after topical DermaVir
Figure 3
Gene expression in the lymph node after topical DermaVir vaccination in mice and monkeys. DermaVir was formulated with reporter plasmid
DNA and applied topically on the skin of mice (representative of two experiments). (a) In situ hybridization using a 35S-labeled Neo-specific sense
probe (negative control) 24 h after DermaVir application. No positive cells were detected by control in situ hybridizations. (b) In situ hybridization
using a 35S-labeled Neo-specific antisense probe on a parallel section of (a). Transduced cells expressing plasmid DNA-derived genes (white silver
grains over the cells). (c) Enlargement of (b). (d) In situ hybridization with a 35S-labeled Neo-specific antisense probe of a lymph node isolated from a
naı¨ve mouse (negative control). (e–g) Immunohistochemical staining with HIV Gag-specific antibody (KC57 FITC, Coulter, Florida) of a mouse lymph
node 72 h post-immunization. DermaVir was formulated with plasmid DNA-expressing gag. (e) Isotype control of p55 antibody (15 s exposure). (f)
p55 antibody staining (5 s exposure) on a parallel section of (d). (g) Protein expression is localized in the paracortical region of the lymph node.
Quantification of these cells in mice revealed an average of 222 (30–400) Gag-expressing cells per 0.05 mm sections, corresponding to an average
of 68 positive cells per mm2. Parallel sections stained with the isotype control gave an average of 0.6 (0–2) positive cells per section. Representative
experiments, repeated at least three times. (h) Gene expression in lymph node dendritic cells (DC) after topical DermaVir vaccination of rhesus
macaques (same methods as in mice (a–c)). Dark-field microscopic image of cells showing (white) silver grains over positive cells. Control
hybridization of a parallel section showed no positive cells (not shown). (i) A single DC expressing Neo gene encoded by the DNA used for DermaVir
formulation. Black dots are silver grains (in situ hybridization) demonstrating plasmid DNA-derived gene expression. The section was also stained
with p55 antibody (anti-human Fascin, 55K-2, Dako Corp. Carpenteria, California) which is a marker for lymph node DC (brown in the figure).
Quantitative analysis in macaques revealed 153 DC expressing DNA per 13.4 mm2 total analyzed sections (average 11 positive cells per mm2).
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vaccination. As demonstrated in Fig 3a and d, in situ hy-
bridizations of parallel sections using a control sense probe
and sections of control mice hybridized with the antisense
probe did not reveal any positive cells. Quantitative analysis
revealed 153 DC expressing DNA per 13.4 mm2 total analy-
zed sections (average 11 positive cells per mm2). These
in situ hybridization results supported the RT-PCR data
(Table I) and suggested that topical DermaVir vaccination
can directly transduce large numbers of skin-derived cells in
the lymph node.
To visualize protein expression, we formulated DermaVir
with pGag and analyzed the lymph nodes with an HIV Gag-
specific antibody (Fig 3e–g). Positive cells were mainly
located in the paracortical area, which is also referred to as
the T cell area known to contain the migrating LC-derived
DC. Altogether, these results further confirmed the RT-PCR
data (Table I) and demonstrated that topical DermaVir vac-
cination results in gene expression in the lymph node.
Since the murine epidermis differs from that of primates
(Foster et al, 1990; Matsue et al, 1993), we performed the
same experiment in rhesus macaques. Our analysis con-
firmed that topical DermaVir vaccination results in DNA-ex-
pressing cells located in the T cell area of the lymph
node (Steinman et al, 1997), specifically in the paracortical
region (Fig 3h). The identity of these positive DNA-express-
ing DC was demonstrated with antibody staining specific
for DC in the lymph node (anti-human Fascin, 55K-2,
Dako Corp., Carpenteria, California) (Steinman et al, 1997)
(Fig 3i). Control hybridization of a parallel section with
the sense probe did not detect positive cells (not shown).
Quantitative analysis revealed 153 DC expressing DNA
per 13.4 mm2 total analyzed sections (average 11 positive
cells per mm2). The number of gene-expressing DC
after topical DermaVir vaccination was quite comparable
with the number of gene-expressing DC detected previ-
ously in the lymph node after ex vivo administration of De-
rmaVir-transduced DC (Lisziewicz et al, 2001). These results
indicated that after topical DermaVir vaccination gene
expression in lymph node DC could be achieved in non-
human primates.
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Figure 4
Induction of simian immunodeficien-
cy virus (SIV)-specific T cells by
DermaVir immunization. SIV-specific
T cell responses were detected in the
peripheral blood of macaques prior to
and 3 wk after the first topical (left
two columns) and ex vivo (right two
columns) DermaVir immunization.
Histograms illustrate SIV-specific T
cells measured as IFN-g expression in
CD8þ and CD8 (gated on CD3) T
lymphocytes after stimulation with
whole chemically inactivated SIV anti-
gen (Lori et al, 2000; Xu et al, 2002).
Numbers represent the percentages of
IFN-g expressing CD8þ , CD3þ , and
CD8, CD3þ T cells in the quadrates.
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Immune responses induced by DermaVir We evaluated
DermaVir-induced immune responses in naı¨ve rhesus mac-
aques, since this is a suitable animal model to study im-
mune-based interventions for HIV. For these studies,
DermaVir was formulated with our prototype therapeutic
plasmid DNA, pSHIV(int-) (Fig 1), that is based on a SHIV
construct. Four monkeys were immunized topically and an-
other four via ex vivo immunization with DermaVir-trans-
duced DC as described previously (Lisziewicz et al, 2001).
SIV-specific T cells were measured in the peripheral blood
after whole SIV viral antigen stimulation by interferon (IFN)-g
production (Fig 4). The average frequency of SIV-specific
CD8þ , CD3þ , and CD8, CD3þ T cells prior to immuniza-
tion was 0.06% and 0.07% (SD¼0.03 and 0.04), respec-
tively, a characteristic background in naı¨ve macaques. After
one immunization all the animals developed SIV-specific
T cell responses. The average frequency of SIV-specific
CD8þ , CD3þ , and CD8, CD3þ T cells in the topically im-
munized group was 0.26% and 0.18% (SD¼ 0.01 and 0.05),
respectively. The average frequency of SIV-specific CD8þ ,
CD3þ , and CD8, CD3þ T cells in the ex vivo immunized
group was 0.27% and 0.28% (SD¼0.15 and 0.11), respec-
tively. These results demonstrate that topical DermaVir im-
munization was able to induce antigen-specific CD8 and
CD4 T cell-mediated immune responses in non-human pri-
mates similar to ex vivo DC vaccination.
Vaccinations were administered at months 0, 2, 5, 13,
and 21. Despite repeated immunizations, antibody respons-
es measured after every vaccination were undetectable by
ELISA in all of the animals, even after the fifth DermaVir
vaccination. After the first vaccination, we consistently de-
tected a transient increase of SIV-specific T cells, peaking
3 wk after vaccination in the peripheral blood; however, 8
wk after vaccination the frequency of SIV-specific cells was
undetectable in the intracellular cytokine assay. Interesting-
ly, after the third vaccination we only sporadically detected
a very low amount of SIV-specific T cells in the peripheral
blood of the animals. Meaningful T cell responses with the
ELISPOT assay were not detected.
To confirm the induction of Th-1-type cell-mediated im-
mune responses by DermaVir, an in vivo assay was used,
similar to that used to determine exposure to Mycobacte-
rium tuberculosis. When people have been exposed to
tuberculosis, a cell-mediated immunity develops that can
be detected as a local response after intradermal injection
of a small amount of tuberculin. These delayed-type hyper-
sensitivity (DTH) responses are mediated by T cells, be-
cause they can be seen in individuals who lack immuno-
globulins. To perform the skin test, we used the same
chemically inactivated SIV (Arthur et al, 1998) that we used
for stimulation of T cells to detect SIV-specific T cells in the
peripheral blood. As control antigen, we used the super-
natant of the parental cell line that was utilized to produce
the SIV (called microvesicles). The skin test was performed
5 mo after the fourth vaccination, when SIV-specific T cell
responses were undetectable by intracellular cytokine as-
say in the peripheral blood. All monkeys immunized either
topically or ex vivo with DermaVir developed DTH respons-
es to SIV antigen but not to the microvesicle control antigen
(Fig 5). The reactive DTH tests in the immunized macaques
further substantiated the activation of T cell-mediated im-
mune responses by DermaVir and suggested the presence
of a memory T cell population in tissue reservoirs that can
expand upon antigenic stimulation.
Discussion
DermaVir is a novel DNA immunization method designed to
improve antigen presentation and induce cytotoxic T cell
responses for the treatment of HIV/AIDS. DermaVir is ap-
plied directly to the epidermis above the basal keratinocytes
to penetrate the skin surface and reach a network of sen-
tinels that serve to initiate immune responses against path-
ogens. After DermaVir immunization, plasmid-derived gene
expression occurred in lymph node DC. Gene-expressing
DC induced T cell-mediated immune responses. Our ex-
periments did not demonstrate cross-presentation of anti-
gens that might also occur. In naı¨ve macaques, DermaVir
effectively primed antigen-specific CD4 helper and CD8 T
cells producing intracellular IFN-g after in vitro antigenic
stimulation. Boosting with DermaVir did not increase T cell
responses in macaques, similar to recent observations in
DC-immunized mice (Ludewig et al, 2001). The possible
explanation for these findings is that DC boosting reacti-
vates memory cytotoxic T lymphocytes (CTL) that can rap-
idly eliminate the antigen-presenting DC and thereby limit
the booster effect, an important mechanism to avoid exag-
gerated CTL responses. But T cell memory was maintained
in the reservoirs, even when SIV-specific T cell frequency
was under the limit of the detection in the peripheral blood
(0.1%), as shown by the DTH responses to SIV antigens in
all the animals immunized either topically or ex vivo with
DermaVir. The reactive DTH test and lack of humoral re-
sponse observed after repeated DermaVir immunizations
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Delayed-type (type IV) simian immunodeficiency virus (SIV)-spe-
cific hypersensitivity (DTH) responses in macaques immunized
topically and ex vivo with DermaVir. DTH skin reactions (diameter,
millimeters) were detected in the skin of macaques 25 wk after the
fourth topical (animals 800, 802, 810, and 813) and ex vivo (animals
798, 805, 806, and 807) DermaVir immunization. DTH reactivity was
measured 72 h post-intradermal injection with 100 mL normal saline
(empty bars); 100 mL control microvesicles (gray bars), representing the
supernatant of the parental cell line that was utilized to produce the SIV
antigen; and 100 mL (2 mg of p27) chemically inactivated SIVmac239
antigen (Arthur et al, 1998) (black bars).
DERMAVIR IMMUNIZATION FOR HIV/AIDS 165124 : 1 JANUARY 2005
are similar to that observed in individuals previously ex-
posed to M. tuberculosis who do not develop antibody
responses and have reactive tuberculin DTH tests. Inter-
estingly, recent studies demonstrated that in M. tuberculosis
infection DC, which are not permissive for the growth of the
bacteria, take up the bacteria and induce cellular immune
responses (Geijtenbeek et al, 2003; Tailleux et al, 2003).
These results are in line with the concept that expression of
antigens within DC will generate polarized cellular respons-
es. The fact that DNA-expressing DC in the lymph node did
not induce antibody production, regardless of the topical or
ex vivo DermaVir vaccination methods, could be explained
by selective antigen expression in DC in the absence
of significant antigen expression in the local somatic cells
(e.g. myocytes, keratinocytes, and fibroblasts), which serve
as antigen reservoirs for conventional DNA vaccines (Tuting
et al, 1998; Akbari et al, 1999).
We have shown here in a primate model that topical
DermaVir vaccination is comparable with ex vivo DC-based
vaccination. DermaVir, administered topically or ex vivo, re-
sulted in a similar number of transduced DC in the lymph
node and induced a similar quantity and quality of SIV-spe-
cific Th1-type T cell responses. Both modalities of DermaVir
administration specifically utilize DC, cells capable of con-
verting naı¨ve T cells to functional cytotoxic T cells and
polarizing the immune system towards T cell-mediated im-
mune responses. Since the immune system of HIV-infected
individuals has already been primed during primary infec-
tion by large amounts of viral antigen, the purpose of
DermaVir therapy is to improve the presentation of viral an-
tigens in order to induce functional T cell responses that can
control viral replication. It is indeed unlikely that HIV-specific
antibodies will have a role in the control of viral load during
established infection (Richman et al, 2003; Wei et al, 2003).
Our experiments demonstrated a remarkably high effi-
ciency of topical gene transfer to lymph node DC. In the
mouse model the efficacy was between 30 and 90 cells per
mm2 and in the primate model 11 cells per mm2 (Fig 3). The
disparity of these numbers might reflect the differences be-
tween the murine and primate epidermis and lymph nodes.
Since the average diameter of a lymph node is, however,
about 1.8 and 6 mm in mice and monkeys, respectively,
when the size of the lymph node was taken into account, a
conservative estimate of the total number of positive cells
per lymph node in the murine model was between 1,000
and 4,000 cells, whereas in the primate model it was about
20,000 cells.
Conventional DNA vaccines designed for prevention of
HIV/SIV infection usually require the optimization of protein
expression to provide a large amount of viral antigens and
thereby induce both antibody and T cell responses in hosts
who have not encountered such antigens. Generally, these
DNA constructs contain one or more codon-optimized HIV
genes driven by a strong constitutive promoter (Barouch
and Letvin, 2000; Corbet et al, 2000; Robinson et al, 2002).
Second-generation plasmid DNAs have been optimized
for high-level expression in cell lines and improved ex-
pression has been shown to be associated with more
efficient induction of immune responses. The plasmid DNA
in DermaVir was designed to express all viral genes in
DC except integrase in order to induce HIV-specific T cells
with broad specificity. HIV-LTR-driven viral protein ex-
pression does not require artificial, codon-optimized se-
quences or heterologous promoters introduced in other
DNA vaccines to achieve efficient expression (Robinson
et al, 2002).
In DermaVir the DNA was formulated with a cationic pol-
ymer (PEIm) in glucose. The cationic polymer complexes
the DNA, forming a small mannosilated particle and the
glucose stabilizes the complex by inhibiting aggregation
prior to the vaccine application. The DermaVir particle con-
tains pathogen-associated molecular patterns (e.g. man-
nose from PEIm and CpG motifs from the plasmid DNA),
and therefore might be recognized by toll like or other re-
ceptors on LC (Akira et al, 2001). PEIm plays an important
role after receptor-mediated endocytosis of DermaVir by
breaking the endosome (Boussif et al, 1995) and facilitating
the trafficking of the DNA into the nucleus, where the DNA-
encoded antigens are expressed (Pollard et al, 1998).
Antigen-presenting DC in the lymph node induce T cell-
mediated anti-tumor immune responses (Banchereau and
Steinman, 1998; Palucka and Banchereau, 1999; Schaden-
dorf and Nestle, 2001). Here, we extended these observa-
tions to DC expressing viral DNA-derived antigens following
topical DermaVir vaccination. These results confirm and
expand the concept of using DC as preferential targets
to elicit cellular immune responses (Kirk and Mule, 2000;
Schadendorf and Nestle, 2001). The technology described
here could provide the basis for novel DNA-based medi-
cines. Various plasmids could be constructed to obtain the
expression of a wide variety of tumor and viral antigens by
DC in the lymph nodes in order to induce antigen-specific T
cell responses. Immune responses might be augmented by
the co-expression of recombinant cytokines (Ahuja et al,
1999; Melero et al, 1999; Ozawa et al, 1999; Takayama et al,
1999). The technology could allow genetic manipulation of
DC to express IL-10, TGF-b, FasL, and CTLA4Ig, for ex-
ample, which have been suggested to enhance tolerance
and allograft survival (Lu et al, 1999). In addition, the tech-
niques described here might be used as tools to elucidate
as yet unanswered questions in immunology, such as the
role of lymph node DC in antigen presentation and immune
induction.
Others have demonstrated inhibition of SIV replication
(Lu et al, 2003) with DC-based ex vivo therapeutic immu-
nization; however, these ex vivo techniques are cum-
bersome, expensive, and limited to highly specialized lab-
oratories. DermaVir represents a significant advancement in
the field of DC-based therapeutic immunization: (i) it can be
manufactured for large-scale human use; (ii) it utilizes a
needle-free, topical application; and (iii) it only requires a
small amount of DNA. (iv) All pre-clinical studies with
DermaVir show no serious safety concerns. Furthermore, (v)
DermaVir suppression of viral load during chronic SIV in-
fection in non-human primates (Lisziewicz et al, in press)
has recently been observed. These features make DermaVir
a promising new approach to the treatment of HIV/AIDS.
Materials and Methods
Plasmid DNA used for DermaVir formulation A plasmid, known
to express green fluorescent protein and neomycin phosphot-
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ransferase, pGFP (Clonetech, Palo Alto, California), was utilized
in most of the experiments demonstrating the mechanism of
DermaVir vaccination. A CMV-driven plasmid expressing the HIV-1
gag protein, Gag-delta8.2 (Naldini et al, 1996), was kindly provided
by Inder Verma. For primate immunology experiments the proto-
type DermaVir plasmid DNA, expressing a replication-defective
virus, was used. The full-length, but integration defective, SHIV
plasmid pSHIV(int-), created by stepwise strategy starting with
p-50SHIV (clone KB9) and p-30SHIV (clone 64/KB9) provided by
Joseph Sodroski of Harvard University, was used in DermaVirSHIV
for all primate experiments. These clones, derivatives of SHIV 89.6,
are also available from the NIH Research and Reference Reagent
Program. First, a clone of p-50SHIV with the deletion of the internal
Bgl2–Bgl2 sites located in the pol gene was created and termed
p-50SHIV(dBg). The internal Bgl2–Bgl2 fragment was mutated by
PCR amplification of the fragment with primers introducing muta-
tions with stop codons and cloned into a separate vector and
termed pBg08. The mutated fragment was isolated and inserted
into p-50SHIV(dBg) to obtain p-50SHIV(int-). The Xho1–Sph1 viral
fragment (6.5 kb) from p-50SHIV(int-) and Sph1–Not1 viral frag-
ment (4.0 Kb) from p-30SHIV clones were isolated and cloned
into a pBluescript (Stratagene Inc., La Jolla, California) vector
backbone to obtain the pSHIV(int-) clone. The sequence of the
junctions and of the integrase gene region of this clone was
checked. It contained small deletions, frame shift, and three sep-
arated stop codons in the integrase gene open reading frame.
It also contained stop codons in the other reading frame in this
region. SIVmac239 sequence: (nt 4696) 5
0-AGATCTAGGGACTTG
GCAAATGGATTGTACCCAT-30 (nt 4729). pSHIV(int-) sequence: 50-
AGATCTATAGATAGATAGCTAGCCCAT-30.
Topical and ex vivo DermaVir immunization DermaVir is for-
mulated to make a approximately 100 nm particle containing DNA,
PEIm, and glucose and the particle size was determined by light
scattering using a Zetasizer (Malvern Instrument, Orsay, France).
For topical DermaVir application, a skin preparation procedure was
developed to allow vaccine penetration to the epidermis. Hair was
removed by shaving and the skin was exfoliated with an exfoliating
sponge (3M Scotch-Brite Heavy Duty Scrub Sponge 3M Corp., St.
Paul, Minnesota), followed by tape stripping (Fig 2). This procedure
results generally in transient and mild erythema but not in hem-
orrhage and eschar formation. 0.2 mL DermaVir was applied on
approximately 40 cm2 prepared skin at four locations: the left and
right upper inguinal region and left and right axillary region. After
30 min of contact time under general anesthesia, DermaVir solution
dried and the animals were returned to the cage. For mice, 0.2 mL
DermaVir was applied on approximately 20 cm2 area on the dor-
sum. In all ex vivo experiments, 106 ex vivo DermaVir-transduced
DC were injected subcutaneously at the same four locations as
previously described (Lisziewicz et al, 2001).
Animals All animal experiments were performed under protocols
approved by an Institutional Animal Care and Use Committee.
Four- to 6-wk-old female BALB/C mice were used. The mice were
anesthetized using methoxyflurane. In non-human primate studies,
rhesus macaques were sedated with ketamine xylazine and placed
on a circulating water heating pad for the duration of the immu-
nization procedure. For the in situ hybridization experiment, the
draining lymph node was surgically removed 24 h after DermaVir
vaccination.
In situ hybridization In situ hybridization was conducted using
standard protocols (Fox and Cottler-Fox, 1993a, b). Riboprobes
were 33P labeled and were determined to detect 20–30 copies per
cell of HIV gag RNA, although in the case of Neo probes the sen-
sitivity was somewhat less. The slides were exposed for 5 d be-
fore development and examination by dark-field microscopy.
Immunohistochemistry was performed using protocols recom-
mended by the supplier of the primary antibodies.
RT-PCR RNA was isolated by using a TRIzol reagent (GIBCO BRL,
Gaithersburg, Mary Land) according to the protocol of the man-
ufacturer. Quantitative RT-PCR were performed with the Roche kit,
detection limit of 200 copies of HIV-1 RNA (Roche Diagnostic
Systems Inc., Branchburg, New Jersey.)
Quantitative determination of SIV-specific T cell responses in
peripheral blood The assay was performed as previously de-
scribed (Lori et al, 2000; Xu et al, 2002). PBMC were plated in
round-bottom 96-microtiter plates (Corning Inc., Corning, New
York) at 0.5 million cells per well in 0.1 mL complete RPMI-1640
medium containing 5 mg Zn-finger-inactivated SIV (kindly provided
by Jeff Lifson, NCI, Frederick, Mary Land) or mock antigen and 50
IU per mL rhIL-2 (gift from Hoffman La Roche). Cells were cultured
for 15 h and treated with Brefeldin A (Sigma, St Louis, Missouri) at
10 mg per mL for an additional 3 h. Cells were collected and ali-
quoted into 0.5 million cells per test tube. After washing once with
2 mL phosphate-buffered saline (PBS) containing 1% bovine se-
rum albumin (BSA), cells were suspended in 0.1 mL PBS/1% BSA
and stained with CD8-Phycoerythrin-Cyanine 5 (PC5; Immunotech,
Marseille, France) and CD3 fluorescein isothiocyanate (FITC; BD
PharMingen, San Diego, California) fluorescent antibodies for 15
min at room temperature. After washing, cells were fixed with 2%
paraformaldehyde, pH 7.4 for 10 min and washed with PBS/1%
BSA, and then permeabilized with 0.1 mL 0.1% saponin in PBS/
1% BSA for 5 min and stained with IFN-g-R-Phycoerythrin con-
jugated (IFN-g-PE; BD PharMingen) antibody for 15 min at room
temperature. After intracellular staining, cells were washed twice
with 1 mL PBS and then re-suspended in a 0.5 mL 1% parafor-
maldehyde PBS buffer. Samples were analyzed by FACS (EPICS
XL-MCL, Coulter, Miami, Florida). A total of 50,000 events were
acquired. Gated CD3þ CD8þ cells were examined for staining
with IFN-g.
Detection of SIV-specific T cell responses in vivo A skin test
was developed to detect SIV-specific T cell responses in vivo. SIV
and control antigens in 0.1 mL physiological salt were intradermally
injected. DTH skin reactions were recorded as the diameter in milli-
meters by a blinded operator 72 h later. The following purified sol-
uble antigens were used: 2 mg (p27) Zn-finger-inactivated SIVmac239
(Arthur et al, 1998); microvesicles as control (the supernatant of the
SupT1 cell line used to produce SIVmac239); and normal saline so-
lution for suspension of antigens (Zinc-inactivated-SIVmac239 and
microvesicles were kindly provided by Jeff Lifson, NCI).
Detection of antibody responses The native SIV p27 used was
purified from conditioned media from infected mammalian cells
(Hut 78) that secrete SIV env and gag proteins. The recombinant
HIV-1 89.6p gp140 protein was prepared from (293) mammalian
cells expressing the gene. To prepare ELISA plates, SIV p27 was
added at 50 ng per well, and gp140 at 50 ng per well. Binding
antibody ELISA titers are routinely presented as the reciprocal of
the serum dilution at which the adsorbance of the test serum is
twice that of negative control serum (Zhao et al, 2003; Patterson
et al, 2004).
We thank N. Miller and M. Ussery (NIAID) for the support of the animal
studies (NIH, NIADS, DAIDS, Contract # NO1-Al-15430), J. Newsome
for his contribution to the murine experiments, and D. Zinn for technical
assistance. We thank J. Lifson and L. Arthur for providing the Zn-finger-
inactivated SIV. We are grateful to S. Petrocchi and T. Battle for their
editorial assistance.
DOI: 10.1111/j.0022-202X.2004.23535.x
Manuscript received December 22, 2003; revised June 30, 2004;
accepted for publication July 20, 2004
Address correspondence to: Julianna Lisziewicz, Research Institute for
Genetic and Human Therapy (RIGHT), Washington, District of Colum-
bia 20007, USA. Email: lisziewj@geneticimmunity.com
DERMAVIR IMMUNIZATION FOR HIV/AIDS 167124 : 1 JANUARY 2005
References
Ahuja SS, Reddick RL, Sato N, et al: Dendritic cell (DC)-based anti-infective
strategies: DCs engineered to secrete IL-12 are a potent vaccine in a
murine model of an intracellular infection. J Immunol 163:3890–3897,
1999
Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B: DNA vac-
cination: Transfection and activation of dendritic cells as key events for
immunity. J Exp Med 189:169–178, 1999
Akira S, Takeda K, Kaisho T: Toll-like receptors: Critical proteins linking innate and
acquired immunity. Nat Immunol 2:675–680, 2001
Amara RR, Robinson HL: A new generation of HIV vaccines. Trends Mol Med
8:489–495, 2002
Arthur LO, Bess JW Jr, Chertova EN, et al: Chemical inactivation of retroviral
infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV
vaccine. AIDS Res Hum Retroviruses 14 (Suppl. 3):311–S319, 1998
Bagnarelli P, Valenza A, Menzo S, Manzin A, Scalise G, Varaldo PE, Clementi M:
Dynamics of molecular parameters of human immunodeficiency virus
type 1 activity in vivo. J Virol 68:2495–2502, 1994
Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature
392:245–252, 1998
Barouch DH, Letvin NL: Dna vaccination for hiv-1 and siv. Intervirology 43:
282–287, 2000
Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF: Risks and benefits of
structured antiretroviral drug therapy interruptions in HIV-1 infection.
AIDS 14:2313–2322, 2000
Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr
JP: A versatile vector for gene and oligonucleotide transfer into cells
in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA 92:
7297–7301, 1995
Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Virologic and immunologic character-
ization of long-term survivors of human immunodeficiency virus type 1
infection. N Engl J Med 332:201–208, 1995
Corbet S, Vinner L, Hougaard DM, Bryder K, Nielsen HV, Nielsen C, Fomsgaard
A: Construction, biological activity, and immunogenicity of synthetic en-
velope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1
isolate (BX08) with human codons. AIDS Res Hum Retroviruses 16:
1997–2008, 2000
Deeks SG, Wrin T, Liegler T, et al: Virologic and immunologic consequences of
discontinuing combination antiretroviral-drug therapy in HIV-infected pa-
tients with detectable viremia. N Engl J Med 344:472–480, 2001
Dieu-Nosjean MC, Vicari A, Lebecque S, Caux C: Regulation of dendritic cell
trafficking: A process that involves the participation of selective
chemokines. J Leukoc Biol 66:252–262, 1999
Foster CA, Yokozeki H, Rappersberger K, et al: Human epidermal T cells pre-
dominantly belong to the lineage expressing alpha/beta T cell receptor.
J Exp Med 171:997–1013, 1990
Fox CH, Cottler-Fox M: In situ hybridization for the detection of HIV RNA in cells
and tissues. In: Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober
W eds. Current Protocols in Immunology. New York: Wiley, 1993a
Fox CH, Cottler-Fox M: In situ hybridization in HIV research. J Microscop Tech
Res 25:78–84, 1993b
Garcia F, Plana M, Ortiz GM, et al: The virological and immunological conse-
quences of structured treatment interruptions in chronic HIV-1 infection.
AIDS 15:F29–F40, 2001
Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Van-
denbroucke-Grauls CM, Appelmelk B, Van Kooyk Y: Mycobacteria tar-
get DC-SIGN to suppress dendritic cell function. J Exp Med 197:7–17,
2003
Harrer T, Harrer E, Kalams SA, et al: Cytotoxic T lymphocytes in asymptomatic
long-term nonprogressing HIV-1 infection. Breadth and specificity of the
response and relation to in vivo viral quasispecies in a person with pro-
longed infection and low viral load. J Immunol 156:2616–2623, 1996
Karlsson GB, Halloran M, Li J, et al: Characterization of molecularly cloned sim-
ian-human immunodeficiency viruses causing rapid CD4þ lymphocyte
depletion in rhesus monkeys. J Virol 71:4218–4225, 1997
Kirk CJ, Mule JJ: Gene-modified dendritic cells for use in tumor vaccines. Hum
Gene Ther 11:797–806, 2000
Klein MR, Van Baalen CA, Holwerda AM, et al: Kinetics of Gag-specific cytotoxic
T lymphocyte responses during the clinical course of HIV-1 infection: A
longitudinal analysis of rapid progressors and long-term asymptomatics.
J Exp Med 181:1365–1372, 1995
Lanzavecchia A, Sallusto F: Dynamics of T lymphocyte responses: Intermediates,
effectors, and memory cells. Science 290:92–97, 2000
Lieberman J, Shankar P, Manjunath N, Andersson J: Dressed to kill? A review of
why antiviral CD8 T lymphocytes fail to prevent progressive immunode-
ficiency in HIV-1 infection. Blood 98:1667–1677, 2001
Lifson JD, Rossio JL, Arnaout R, et al: Containment of simian immunodeficiency
virus infection: Cellular immune responses and protection from rechal-
lenge following transient postinoculation antiretroviral treatment. J Virol
74:2584–2593, 2000
Lisziewicz J, Bakare N, Lori F: Therapeutic vaccination for future management of
HIV/AIDS. Vaccine 21:620–623, 2003
Lisziewicz J, Gabrilovich DI, Varga G, et al: Induction of potent human immuno-
deficiency virus type 1-specific T-cell-restricted immunity by genetically
modified dendritic cells. J Virol 75:7621–7628, 2001
Lisziewicz J, Rosenberg E, Lieberman J, et al: Control of HIV despite the dis-
continuation of antiretroviral therapy. N Engl J Med 340:1683–1684,
1999
Lori F, Lewis MG, Xu J, et al: Control of SIV rebound through structured treatment
interruptions during early infection. Science 290:1591–1593, 2000
Lori F, Lisziewicz J: Structured treatment interruptions for the management of HIV
infection. JAMA 286:2981–2987, 2001
Lori F, Rosenberg E, Lieberman J, et al: Hydroxyurea and didanosine long-term
treatment prevents HIV breakthrough and normalizes immune parame-
ters. AIDS Res Hum Retroviruses 15:1333–1338, 1999
Ludewig B, Mccoy K, Pericin M, et al: Rapid peptide turnover and inefficient
presentation of exogenous antigen critically limit the activation of self-
reactive CTL by dendritic cells. J Immunol 166:3678–3687, 2001
Lu L, Lee WC, Takayama T, Qian S, Gambotto A, Robbins PD, Thomson AW:
Genetic engineering of dendritic cells to express immunosuppressive mol-
ecules (viral IL-10, TGF-beta, and CTLA4Ig). J Leukoc Biol 66:293–296,
1999
Lu W, Wu X, Lu Y, Guo W, Andrieu JM: Therapeutic dendritic-cell vaccine for
simian AIDS. Nat Med 9:27–32, 2003
Masopust D, Vezys V, Marzo AL, Lefrancois L: Preferential localization of effector
memory cells in nonlymphoid tissue. Science 291:2413–2417, 2001
Matsue H, Bergstresser PR, Takashima A: Reciprocal cytokine-mediated cellular
interactions in mouse epidermis: Promotion of gamma delta T-cell growth
by IL-7 and TNF alpha and inhibition of keratinocyte growth by gamma
IFN. J Invest Dermatol 101:543–548, 1993
Melero I, Duarte M, Ruiz J, et al: Intratumoral injection of bone-marrow derived
dendritic cells engineered to produce interleukin-12 induces complete
regression of established murine transplantable colon adenocarcinomas.
Gene Ther 6:1779–1784, 1999
Miller V, Sabin C, Hertogs K, et al: Virological and immunological effects of
treatment interruptions in HIV-1 infected patients with treatment failure.
AIDS 14:2857–2867, 2000
Naldini L, Blomer U, Gallay P, et al: In vivo gene delivery and stable transduction
of nondividing cells by a lentiviral vector. Science 272:263–267, 1996
Ogg GS, Jin X, Bonhoeffer S, et al: Quantitation of HIV-1-specific cytotoxic T
lymphocytes and plasma load of viral RNA. Science 279:2103–2106,
1998
Ozawa H, Ding W, Torii H, et al: Granulocyte-macrophage colony-stimulating
factor gene transfer to dendritic cells or epidermal cells augments their
antigen-presenting function including induction of anti-tumor immunity.
J Invest Dermatol 113:999–1005, 1999
Palucka K, Banchereau J: Dendritic cells: A link between innate and adaptive
immunity. J Clin Immunol 19:12–25, 1999
Patterson LJ, Malkevitch N, Venzon D, et al: Protection against mucosal simian
immunodeficiency virus SIV(mac251) challenge by using replicating
adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol
78:2212–2221, 2004
Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, Picker LJ:
HIV-1-specific CD4þ T cells are detectable in most individuals with ac-
tive HIV-1 infection, but decline with prolonged viral suppression. Nat
Med 5:518–525, 1999
Pollard H, Remy JS, Loussouarn G, Demolombe S, Behr JP, Escande D: Poly-
ethylenimine but not cationic lipids promotes transgene delivery to the
nucleus in mammalian cells. J Biol Chem 273:7507–7511, 1998
Pontesilli O, Carotenuto P, Kerkhof-Garde SR, et al: Lymphoproliferative response
to HIV type 1 p24 in long-term survivors of HIV type 1 infection is pre-
dictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses
15:973–981, 1999
Reimann KA, Li JT, Voss G, et al: An env gene derived from a primary human
immunodeficiency virus type 1 isolate confers high in vivo replicative ca-
pacity to a chimeric simian/human immunodeficiency virus in rhesus
monkeys. J Virol 70:3198–3206, 1996
Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK: Visualizing the generation
of memory CD4 T cells in the whole body. Nature 410:101–105, 2001
Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing
antibody response to HIV type 1 infection. Proc Natl Acad Sci USA
100:4144–4149, 2003
168 LISZIEWICZ ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Robinson LG, Hilinski J, Graham F, Hymes L, Beck-Sague CM, Hsia J, Nesheim
SR: Predictors of cytomegalovirus disease among pediatric transplant
recipients within one year of renal transplantation. Pediatr Transplant
6:111–118, 2002
Rosenberg ES, Altfeld M, Poon SH, et al: Immune control of HIV-1 after early
treatment of acute infection. Nature 407:523–526, 2000
Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA,
Walker BD: Vigorous HIV-1-specific CD4þ T cell responses associated
with control of viremia. Science 278:1447–1450, 1997
Rowland-Jones SL: HIV: The deadly passenger in dendritic cells. Curr Biol 9:
248–R250, 1999
Ruiz L, Carcelain G, Martinez-Picado J, et al: HIV dynamics and T-cell immunity
after three structured treatment interruptions in chronic HIV-1 infection.
AIDS 15:F19–F27, 2001
Schadendorf D, Nestle FO: Autologous dendritic cells for treatment of advanced
cancer—an update. Recent Results Cancer Res 158:236–248, 2001
Schmitz JE, Kuroda MJ, Santra S, et al: Control of viremia in simian immuno-
deficiency virus infection by CD8þ lymphocytes. Science 283:857–860,
1999
Steinman R, Hoffman L, Pope M: Maturation and migration of cutaneous den-
dritic cells. J Invest Dermatol 105:2S–7S, 1995
Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev
Immunol 9:271–296, 1991
Steinman RM, Pack M, Inaba K: Dendritic cells in the T-cell areas of lymphoid
organs. Immunol Rev 156:25–37, 1997
Tailleux L, Schwartz O, Herrmann JL, et al: DC-SIGN is the major Mycobacterium
tuberculosis receptor on human dendritic cells. J Exp Med 197:121–127,
2003
Takayama T, Tahara H, Thomson AW: Transduction of dendritic cell progenitors
with a retroviral vector encoding viral interleukin-10 and enhanced green
fluorescent protein allows purification of potentially tolerogenic antigen-
presenting cells. Transplantation 68:1903–1909, 1999
Tuting T, Storkus WJ, Falo LD Jr: DNA immunization targeting the skin: Molecular
control of adaptive immunity. J Invest Dermatol 111:183–188, 1998
Vogel TU, Horton H, Fuller DH, et al: Differences between T cell epitopes recog-
nized after immunization and after infection. J Immunol 169:4511–4521,
2002
Von Andrian UH, Mackay CR: T-cell function and migration. Two sides of the
same coin. N Engl J Med 343:1020–1034, 2000
Wei X, Decker JM, Wang S, et al: Antibody neutralization and escape by HIV-1.
Nature 422:307–312, 2003
Xu J, Whitman L, Lori F, Lisziewicz J: Quantification of HIV-specific CD8 T cells by
in vitro stimulation with inactivated viral particles. AIDS 16:1849–1857,
2002
Zhao J, Lou Y, Pinczewski J, et al: Boosting of SIV-specific immune responses in
rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and
Ad5hr-SIVgag recombinants. Vaccine 21:4022–4035, 2003
Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H: Antigen
localisation regulates immune responses in a dose- and time-dependent
fashion: A geographical view of immune reactivity. Immunol Rev 156:
199–209, 1997
DERMAVIR IMMUNIZATION FOR HIV/AIDS 169124 : 1 JANUARY 2005
